Clostridioides Difficile guidelines (IDSA, 2021)

Guidelines for noninvasive tests for evaluation of Clostridioides difficile severity and prognosis were published in September 2021 by the Infectious Diseases Society of America and Society for Healthcare Epidemiology of America in Clinical Infectious Diseases.

These are some of the highlights of the guidelines without analysis or commentary. For more information, go directly to the guidelines by clicking the link in the reference.

Updated guidelines on the management of Clostridioides difficile infection in adults were published in September 2021 by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) in Clinical Infectious Diseases.^[1]

In patients with a first Clostridioides difficile infection (CDI) episode, fidaxomicin is recommended instead of a standard course of vancomycin.

In those with recurrent CDI episodes, fidaxomicin (standard or extended-pulsed regimen), rather than a standard course of vancomycin, is recommended.

In patients who experience a recurrent CDI episode within the last 6 months, use bezlotoxumab as a co-intervention in combination with standard-of-care (SOC) antibiotics rather than SOC antibiotics only.

For more information, please go to Clostridioides (Clostridium) difficile Colitis. For more Clinical Practice Guidelines, please go to Guidelines.

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Clostridioides difficile Clinical Practice Guidelines (IDSA/SHEA, 2021) - Medscape - Nov 03, 2021.

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

My Alerts